BAC Water 10mL
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.

SKU: PW-013 • Batch: PW-260312
Synergistic blend of CJC-1295 (GHRH analogue) and Ipamorelin (GHRP) studied for amplified GH release, body composition, and recovery research.
Read the full description ↓✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Dispatched next business day (orders before 11PM AEST)
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.
Purity independently verified at a leading Australian university via HPLC & mass spectrometry.
CJC-1295 + Ipamorelin is a synergistic research blend combining two complementary growth hormone secretagogues. CJC-1295 (with DAC) is a modified GHRH analogue with an extended half-life achieved via Drug Affinity Complex (DAC) technology that covalently binds to serum albumin, greatly prolonging its circulating half-life relative to native GHRH. Ipamorelin is a selective third-generation GHRP that mimics ghrelin at the GHS-R1a receptor without significantly elevating cortisol or prolactin at research-relevant concentrations.
Together, they act on distinct receptor pathways: CJC-1295 stimulates the GHRH receptor while Ipamorelin activates the ghrelin/GHS-R1a receptor, amplifying pulsatile GH release beyond what either compound achieves alone. Research has explored this combination for body composition, recovery, sleep quality, and metabolic applications.
The selectivity of Ipamorelin for GH release with minimal impact on cortisol and prolactin distinguishes it from earlier-generation GHRPs (GHRP-2, GHRP-6) and makes it a preferred research tool when studying GH axis modulation in isolation.
CJC-1295 + Ipamorelin is supplied strictly as a research chemical for in-vitro laboratory use. It is not approved for human therapeutic use in Australia and is not for human or animal consumption. Researchers are responsible for compliance with TGA regulations and their institution's protocols.
We target 99% or higher purity. Every batch is analysed by HPLC and mass spectrometry and ships with a Certificate of Analysis; select batches also undergo independent, third-party purity verification at a leading Australian university.
Yes, every batch ships with a batch-specific COA documenting HPLC purity and mass-spectrometry identity. You can view sample reports on our Lab Reports page.
CJC-1295 + Ipamorelin can be ordered here from Peptide Labs for in-vitro research use, dispatched domestically within Australia with a COA included.
No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.
CJC-1295 + Ipamorelin 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
A triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial.
Recent peer-reviewed studies from PubMed related to CJC-1295 + Ipamorelin. Provided for research context — not medical advice.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, et al. · The American journal of sports medicine · 2026
PMID: 41476424
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026
PMID: 41966639
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · International journal of molecular sciences · 2026
PMID: 42123471
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.